Preliminary net revenue increased 73% to $72.5 million for Q1 2025, compared to $41.9 million in Q1 2024Achieved preliminary GAAP net income of $4.5 million, or $0.27 per shareReported preliminary Q1 2025 Adjusted EBITDA of $7.8 millionQuarter-end cash balance of $26.7 million, up from $22.8 million as of December 31, 2024Financial results conference call and webcast to be held on May 12, 2025 at 4:30 pm ET POMPANO BEACH, Fla., May 12, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM) (the “Co ...